JP7037577B2 - 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 - Google Patents

高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 Download PDF

Info

Publication number
JP7037577B2
JP7037577B2 JP2019550622A JP2019550622A JP7037577B2 JP 7037577 B2 JP7037577 B2 JP 7037577B2 JP 2019550622 A JP2019550622 A JP 2019550622A JP 2019550622 A JP2019550622 A JP 2019550622A JP 7037577 B2 JP7037577 B2 JP 7037577B2
Authority
JP
Japan
Prior art keywords
seq
cells
cell
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019550622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509767A (ja
JP2020509767A5 (https=
Inventor
アウディ シャピュイ，
トーマス シュミット，
メーガン マカフィー，
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2020509767A publication Critical patent/JP2020509767A/ja
Publication of JP2020509767A5 publication Critical patent/JP2020509767A5/ja
Application granted granted Critical
Publication of JP7037577B2 publication Critical patent/JP7037577B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
JP2019550622A 2017-03-15 2018-03-15 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 Expired - Fee Related JP7037577B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471956P 2017-03-15 2017-03-15
US62/471,956 2017-03-15
PCT/US2018/022759 WO2018170338A2 (en) 2017-03-15 2018-03-15 High affinity mage-a1-specific tcrs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021039957A Division JP2021090462A (ja) 2017-03-15 2021-03-12 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用

Publications (3)

Publication Number Publication Date
JP2020509767A JP2020509767A (ja) 2020-04-02
JP2020509767A5 JP2020509767A5 (https=) 2021-04-22
JP7037577B2 true JP7037577B2 (ja) 2022-03-16

Family

ID=63523985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550622A Expired - Fee Related JP7037577B2 (ja) 2017-03-15 2018-03-15 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
JP2021039957A Pending JP2021090462A (ja) 2017-03-15 2021-03-12 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021039957A Pending JP2021090462A (ja) 2017-03-15 2021-03-12 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用

Country Status (13)

Country Link
US (2) US11034748B2 (https=)
EP (1) EP3595708A4 (https=)
JP (2) JP7037577B2 (https=)
KR (1) KR102375033B1 (https=)
CN (1) CN110582299A (https=)
AU (1) AU2018234830B2 (https=)
BR (1) BR112019018863A8 (https=)
CA (1) CA3055983A1 (https=)
EA (1) EA201992131A1 (https=)
IL (1) IL269250A (https=)
MX (1) MX2019010972A (https=)
SG (1) SG11201908527SA (https=)
WO (1) WO2018170338A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3440106T3 (da) 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
JP7037577B2 (ja) * 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
CA3097396A1 (en) * 2018-04-19 2019-10-24 Baylor College Of Medicine Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
SG11202111865UA (en) 2019-05-01 2021-11-29 Pact Pharma Inc Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
EP4103284A1 (en) * 2020-02-14 2022-12-21 Adaptimmune Limited Method of treatment of cancer or tumour
CN111320703A (zh) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 靶向cd22的嵌合抗原受体及其应用
CN111499763A (zh) * 2020-03-31 2020-08-07 江苏省省级机关医院 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用
EP4149631A1 (en) * 2020-05-13 2023-03-22 Adaptimmune Limited Method of treatment of cancer or tumour
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
AU2022204581B2 (en) * 2021-04-14 2023-04-13 Tscan Therapeutics, Inc. Binding proteins recognizing HA-2 antigen and uses thereof
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
EP4430402A1 (en) 2021-11-09 2024-09-18 T-Knife GmbH Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
CN116063457A (zh) * 2022-04-27 2023-05-05 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
EP4534554A1 (en) * 2022-06-01 2025-04-09 Corregene Biotechnology Co., Ltd. Mage-a1 specific tcr and use thereof
NL2032130B1 (en) * 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025146286A1 (en) * 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505635A (ja) 2013-01-29 2016-02-25 マックス−デルブリュック−セントラム フュア モレクラーレ メディツィン（エムディーシー） ベルリン−ブッフ Ｍａｇｅ−ａ１を認識する高結合活性結合分子

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
CA2700436C (en) * 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
CA2839663A1 (en) * 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
EP3404111A1 (en) * 2013-03-13 2018-11-21 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
KR102415259B1 (ko) * 2013-11-22 2022-06-30 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
PT3514172T (pt) * 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
ES2841274T3 (es) * 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
WO2016040900A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
WO2016179006A1 (en) * 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CN106188274A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别rhamm抗原短肽的t细胞受体
EA201792660A1 (ru) * 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх Библиотека т-клеточных рецепторов
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN105316362B (zh) * 2015-08-19 2020-03-17 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
KR102436129B1 (ko) * 2016-06-17 2022-08-26 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 및 이의 용도
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
JP7037577B2 (ja) * 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505635A (ja) 2013-01-29 2016-02-25 マックス−デルブリュック−セントラム フュア モレクラーレ メディツィン（エムディーシー） ベルリン−ブッフ Ｍａｇｅ−ａ１を認識する高結合活性結合分子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gene Therapy (2005) 12, 140-146

Also Published As

Publication number Publication date
CA3055983A1 (en) 2018-09-20
WO2018170338A3 (en) 2019-11-21
IL269250A (en) 2019-11-28
BR112019018863A2 (pt) 2020-04-14
AU2018234830A1 (en) 2019-09-26
BR112019018863A8 (pt) 2023-05-02
KR20190129082A (ko) 2019-11-19
EP3595708A4 (en) 2020-12-16
WO2018170338A2 (en) 2018-09-20
US20210355189A1 (en) 2021-11-18
US20200017568A1 (en) 2020-01-16
SG11201908527SA (en) 2019-10-30
KR102375033B1 (ko) 2022-03-15
EA201992131A1 (ru) 2020-02-06
JP2020509767A (ja) 2020-04-02
JP2021090462A (ja) 2021-06-17
MX2019010972A (es) 2019-12-02
AU2018234830B2 (en) 2023-03-02
US11034748B2 (en) 2021-06-15
CN110582299A (zh) 2019-12-17
EP3595708A2 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
JP7037577B2 (ja) 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
US20240279307A1 (en) Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
US20210069241A1 (en) Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US12398191B2 (en) BRAF-specific TCRs and uses thereof
JP2020535796A (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
JP7611844B2 (ja) 高アビディティｗｔ１ｔ細胞受容体とその使用
TW202317602A (zh) 嵌合多肽
KR20210049119A (ko) Kras 또는 her2 항원을 표적으로 하는 면역요법
JP2020533289A (ja) 養子細胞治療を改善するための方法
US12595290B2 (en) T cell receptors specific for mesothelin and their use in immunotherapy
JP7737978B2 (ja) Ｗｔ－１に特異的なｔ細胞免疫療法
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
WO2022076353A1 (en) Compositions and methods for treating mage-a1-expressing disease
HK40073285A (en) T-cell immunotherapy specific for wt-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210312

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210913

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20211213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220304

R150 Certificate of patent or registration of utility model

Ref document number: 7037577

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees